ISSN 2410-7751 (Print)
ISSN 2410-776X (Online)

Biotechnologia Acta Т. 18, No. 2, 2025
P.  , Bibliography 16 , Engl.

UDC

The Anticancer Effect of RAD51-IN-1 in MDAH-2774 (CVCL_0420) Cells
Deniz ÖZDEMİR, Can Ali AĞCA
Department of Molecular Biology and Genetics, Bingöl University, 12000, Bingöl, TÜRKİYE
Aim: This study aimed to investigate the effect of pharmacological inhibition of RAD51, via RAD51-IN-1, on the MDAH-2774 cell line
Methods: To achieve these objectives, firstly, MDAH-2774 cells were treated with different doses of RAD51-IN-1 to determine the effects on cell viability and the IC50 value of RAD51-IN-1. Intracellular ROS levels of the cells were investigated by DCFDA staining and their migration abilities were examined by wound healing test. In the last set of experiments, the effect of RAD51-IN-1 monotherapy application on cell death was investigated by acridine orange/ethidium bromide staining.
Results: In the experimental findings obtained, firstly, cells were treated with different doses of RAD51-IN-1 to decrease cell viability and IC50 of RAD51-IN-1 was determined. In addition, it was observed that the amount of intracellular ROS increased after DCFDA staining after RAD51-IN-1 treatment. In the last set of experiments, it was determined that cell death occurred with increasing doses following acridine orange/ethidium bromide staining of RAD51-IN-1.
Conclusion: The RAD51-IN-1 small molecule inhibitor is a promising approach for treating ovarian cancer, but the drug requires further in vitro evaluation.
Keywords: Ovarian Cancer, RAD51-IN-1, ROS, Cell Death.

© Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, 2025